TNF Pharmaceuticals (LTS:0A8D) Beginning Cash Position : $0.17 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is TNF Pharmaceuticals Beginning Cash Position?

TNF Pharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2025 was $0.17 Mil.

TNF Pharmaceuticals's quarterly Beginning Cash Position increased from Sep. 2024 ($0.54 Mil) to Dec. 2024 ($1.19 Mil) but then declined from Dec. 2024 ($1.19 Mil) to Mar. 2025 ($0.17 Mil).

TNF Pharmaceuticals's annual Beginning Cash Position increased from Dec. 2022 ($0.56 Mil) to Dec. 2023 ($0.75 Mil) and increased from Dec. 2023 ($0.75 Mil) to Dec. 2024 ($2.68 Mil).

TNF Pharmaceuticals Beginning Cash Position Historical Data

The historical data trend for TNF Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TNF Pharmaceuticals Beginning Cash Position Chart

TNF Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

0.14

0.15

0.56

0.75

2.68

TNF Pharmaceuticals Quarterly Data
	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Beginning Cash Position	Get a 7-Day Free Trial															2.68	0.23	0.54	1.19	0.17

TNF Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

TNF Pharmaceuticals Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of TNF Pharmaceuticals's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

TNF Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

TNFA:USA

Address

855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://tnfpharma.com

TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

TNF Pharmaceuticals Headlines

No Headlines